Biktarvy is the most prescribed HIV treatment in the world, but it is not the only option — and for some patients it may not be the best one. Whether you are newly diagnosed and exploring first-line choices, experiencing side effects, facing cost barriers, or simply asking whether a switch makes clinical sense, understanding the available alternatives is a reasonable and important conversation to have with your HIV clinician.
This page compares the main guideline-recommended Biktarvy alternatives, including what is available as a licensed generic in India, pricing, key clinical differences, and the questions you should ask your clinician before any switch.
This is not switching guidance. Antiretroviral therapy decisions must be made with your HIV clinician. This page provides clinical context to inform that conversation — it does not constitute medical advice and does not replace a consultation with your prescriber.
Why Patients Consider Biktarvy Alternatives
- Cost: Brand Biktarvy is $4,216/month in the US. Generic B/F/TAF from India is $150/month. Generic dolutegravir-based alternatives may cost less.
- Side effects: Some patients experience insomnia, vivid dreams, or weight changes on integrase inhibitor-based regimens and explore alternatives.
- Simplification: Patients with strong adherence records sometimes switch to a two-drug regimen such as Dovato to reduce pill burden or long-term drug exposure.
- Comorbidities: Renal impairment, bone density concerns, or cardiovascular risk factors can influence regimen selection.
- Hepatitis B coinfection: Biktarvy is active against HBV due to its emtricitabine and TAF components. Any switch for an HBV-coinfected patient must include agents active against HBV.
- Drug interactions: Biktarvy interacts with antacids, certain supplements, and rifampicin. Patients on complex polypharmacy may need an interaction review.
The Main Biktarvy Alternatives
Dovato is a two-drug regimen (2DR) combining dolutegravir (an integrase inhibitor) and lamivudine (an NRTI). It achieves viral suppression rates comparable to three-drug regimens in treatment-naïve patients with baseline viral loads below 500,000 copies/mL, as demonstrated in the GEMINI-1 and GEMINI-2 phase 3 trials. The two-drug backbone means less long-term drug exposure compared to a three-drug regimen.
Not suitable for: patients with hepatitis B coinfection; patients with HIV RNA ≥500,000 copies/mL at baseline; patients with suspected or confirmed lamivudine or integrase resistance.
Generic dolutegravir/lamivudine is available from Indian manufacturers under MPP license, typically priced around $60–$90 per month.
Triumeq is a three-drug regimen built around dolutegravir with abacavir and lamivudine as the NRTI backbone. Dolutegravir’s resistance barrier is high — comparable to bictegravir.
Important: HLA-B*5701 testing is required before prescribing abacavir. Approximately 5–8% of white patients carry the HLA-B*5701 allele associated with abacavir hypersensitivity syndrome (AHS), which can be severe or fatal. Triumeq may be less preferred in patients with cardiovascular risk factors.
Generic abacavir/dolutegravir/lamivudine is available from Indian manufacturers, typically priced around $70–$95 per month.
Symtuza is a protease inhibitor (PI)-based regimen using darunavir boosted by cobicistat. It is generally reserved for situations where integrase inhibitors are not appropriate or preferred — such as patients with documented integrase resistance. Cobicistat has significant drug interaction potential and also affects serum creatinine measurements (a functional effect, not actual renal toxicity).
Generic darunavir and cobicistat-based combinations have more limited availability in India compared to dolutegravir-based options.
Juluca is a two-drug switch regimen indicated for virologically suppressed adults switching from a stable regimen — not for treatment-naïve patients. The SWORD-1 and SWORD-2 trials demonstrated non-inferior viral suppression rates in suppressed patients switching to Juluca.
Restrictions apply: No prior virological failure or resistance to dolutegravir or rilpivirine; no current or anticipated use of proton pump inhibitors; must be taken with a substantial meal (≥500 kcal). Rilpivirine is associated with depression and insomnia in some patients.
Delstrigo is an NNRTI-based three-drug regimen built around doravirine, a newer NNRTI with a favorable resistance profile compared to older agents like efavirenz. It is associated with less CNS toxicity than efavirenz and has a flat effect on lipids. Doravirine has a moderate resistance barrier — lower than dolutegravir or bictegravir.
Delstrigo uses tenofovir disoproxil fumarate (TDF) rather than TAF. TDF should be used with caution in patients with or at risk of renal impairment or low bone mineral density. Generic doravirine-based combinations from India have limited availability.
Side-by-Side Clinical Comparison
| Regimen | Drugs | Class | Resistance Barrier | HBV Active? | India Generic |
|---|---|---|---|---|---|
| Biktarvy | BIC/FTC/TAF | INSTI + 2 NRTIs | Very high | Yes (FTC + TAF) | Yes — ~$150/mo |
| Dovato | DTG/3TC | INSTI + NRTI (2DR) | High | No | Yes — ~$70/mo |
| Triumeq | ABC/DTG/3TC | INSTI + 2 NRTIs | High | Limited | Yes — ~$80/mo |
| Symtuza | DRV/COBI/FTC/TAF | PI/COBI + 2 NRTIs | High | Yes (FTC + TAF) | Limited |
| Juluca | DTG/RPV | INSTI + NNRTI (2DR) | Moderate–high | No | Limited |
| Delstrigo | DOR/3TC/TDF | NNRTI + 2 NRTIs | Moderate | Limited | Limited |
Which Patients May Benefit From a Switch Away From Biktarvy?
Patients Considering Dovato (DTG/3TC)
Good candidates are virologically suppressed patients with no prior virological failure, no documented integrase or lamivudine resistance, no hepatitis B coinfection, and a desire to reduce overall drug exposure with a two-drug regimen. The TANGO trial demonstrated maintained suppression in patients switching from TDF-based regimens to Dovato.
Patients Considering a Switch for Cost Reasons
If cost is the primary driver, the choice between generic B/F/TAF (~$150/month from India) and generic DTG/3TC (~$70/month) requires clinical input. Patients with HBV coinfection cannot switch to DTG/3TC. Patients with prior lamivudine exposure or documented lamivudine resistance are not suitable for DTG/3TC. For appropriate patients, generic DTG/3TC from India offers the lowest cost among guideline-recommended options with generic availability.
Never switch antiretroviral therapy without clinician guidance. Switching between regimens without resistance history review, appropriate monitoring, and medical oversight risks virological failure and development of resistance mutations that may narrow future treatment options permanently.
Generic Availability From India: What Is Available
| Generic | Brand Equivalent | MPP License | Approx. India Price | Availability |
|---|---|---|---|---|
| B/F/TAF | Biktarvy | Yes (Hetero, Cipla) | ~$150/mo | Good |
| DTG/3TC | Dovato | Yes (multiple) | ~$60–70/mo | Excellent |
| ABC/DTG/3TC | Triumeq | Yes (multiple) | ~$70–95/mo | Good |
| DRV/COBI/FTC/TAF | Symtuza | Partial | Varies | Limited |
| DTG/RPV | Juluca | Limited | Varies | Limited |
| DOR/3TC/TDF | Delstrigo | Limited | Varies | Limited |
Questions to Ask Your HIV Clinician
- Do I have any documented resistance mutations that would limit my options?
- Am I coinfected with hepatitis B? (Eliminates DTG/3TC and other non-HBV-active regimens)
- Have I had my HLA-B*5701 status tested? (Required before any abacavir-containing regimen)
- What is my current eGFR and have I had any renal issues? (Affects TDF vs. TAF preference)
- What is my cardiovascular risk profile? (Relevant for abacavir-containing regimens)
- Are there any current drug interactions I should be aware of with my other medications?
- If I switch to a generic from India, how should I monitor, and what should I do if my viral load becomes detectable?
Related Pages on Sunny Pharma
- What is the generic name for Biktarvy? Complete 2026 guide
- Biktarvy price in India 2026: licensed generic pricing explained
- How to buy licensed generic Biktarvy from India
- Biktarvy cost without insurance: every assistance program explained
- Biktarvy side effects: complete 5-year clinical data
Frequently Asked Questions
The main guideline-recommended alternatives include Dovato (dolutegravir/lamivudine), Triumeq (abacavir/dolutegravir/lamivudine), Symtuza (darunavir/cobicistat/emtricitabine/TAF), Juluca (dolutegravir/rilpivirine), and Delstrigo (doravirine/lamivudine/TDF). The right choice depends on your resistance history, comorbidities, hepatitis B status, and treatment history.
For appropriate patients, yes. Dovato (dolutegravir/lamivudine) is a guideline-preferred two-drug option for treatment-naïve patients with viral loads below 500,000 copies/mL and no hepatitis B coinfection. Generic DTG/3TC from India is available at approximately $60–$70 per month. It is not suitable for patients with hepatitis B or documented lamivudine resistance.
Both are guideline-recommended three-drug regimens with high-resistance-barrier integrase inhibitors. Biktarvy uses the TAF backbone with better renal and bone safety data. Triumeq requires HLA-B*5701 testing and is less preferred in patients with cardiovascular risk factors. Generic ABC/DTG/3TC from India is available and less expensive than generic B/F/TAF.
Potentially yes, depending on your clinical profile. Generic DTG/3TC is available from India at approximately $60–$70/month — about half the cost of generic B/F/TAF. However, a switch requires clinician review of your resistance history, HBV status, and a viral load monitoring plan. Do not switch antiretroviral therapy without medical supervision.
Among guideline-recommended options, generic dolutegravir/lamivudine (Dovato equivalent) is the most affordable option available from India at approximately $60–$70 per month for appropriate patients. Generic abacavir/dolutegravir/lamivudine (Triumeq equivalent) is approximately $70–$95. Generic B/F/TAF (Biktarvy equivalent) is approximately $150. Suitability depends on your individual clinical factors.
Yes. Generic dolutegravir and dolutegravir-based combinations including DTG/3TC and ABC/DTG/3TC are available from MPP-licensed Indian manufacturers. Generic dolutegravir has been available in India longer than generic bictegravir and is produced by multiple manufacturers including Hetero Labs and Cipla.
Biktarvy itself (B/F/TAF) has favorable renal safety due to TAF’s low plasma exposure. For patients with significant chronic kidney disease, dolutegravir/lamivudine (no nephrotoxic NRTI) may also be appropriate. TDF-containing regimens (Delstrigo) are generally avoided in patients with eGFR below 50 mL/min. Consult your HIV clinician and nephrologist for personalized guidance.
Abacavir-containing regimens (Triumeq) require HLA-B*5701 testing before prescribing. Biktarvy and dolutegravir/lamivudine regimens do not. All patients starting or switching ART should have resistance testing to guide regimen selection.
Yes. All the main alternatives discussed — Dovato, Triumeq, Symtuza, Juluca, and Delstrigo — are once-daily regimens. Twice-daily regimens are generally only used in specific clinical situations such as confirmed first-generation integrase inhibitor resistance.
Patients with HIV/HBV coinfection should remain on a regimen with full HBV activity. Biktarvy (FTC + TAF) is active against both. Acceptable alternatives that maintain HBV coverage include Symtuza (FTC + TAF). Regimens without dual HBV-active agents (such as DTG/3TC alone, ABC/DTG/3TC, or Juluca) are contraindicated in HBV coinfection. Abruptly stopping HBV-active therapy can cause severe hepatitis B flares.
How we reviewed this article:
Sunny Pharma follows strict sourcing guidelines and relies on peer-reviewed studies, government agencies (FDA, CMS, HRSA), academic research institutions, and medical associations. We use only credible, verifiable sources to ensure accuracy.
Read our editorial policy →Sources & References
- DHHS Panel on Antiretroviral Guidelines. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents: clinicalinfo.hiv.gov
- Cahn P et al. GEMINI-1 and GEMINI-2: Dolutegravir plus lamivudine versus dolutegravir plus tenofovir DF/emtricitabine (2019): PubMed
- Gallant J et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine. The Lancet, 2017.
- van Wyk J et al. TANGO: Switching from TDF-based triple-drug regimen to DTG/3TC: PubMed
- FDA. Biktarvy Prescribing Information (2025): accessdata.fda.gov
- FDA. Dovato Prescribing Information: accessdata.fda.gov
- Medicines Patent Pool. Licenses: medicinespatentpool.org